Aptose Biosciences, Inc. (APTO): Price and Financial Metrics


Aptose Biosciences, Inc. (APTO)

Today's Latest Price: $6.50 USD

0.26 (4.17%)

Updated Jul 2 4:00pm

Add APTO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

APTO Daily Price Range
APTO 52-Week Price Range

APTO Stock Price Chart Technical Analysis Charts


APTO Price/Volume Stats

Current price $6.50 52-week high $9.25
Prev. close $6.24 52-week low $1.82
Day low $6.26 Volume 350,773
Day high $6.61 Avg. volume 913,899
50-day MA $7.21 Dividend yield N/A
200-day MA $5.41 Market Cap 580.26M

Aptose Biosciences, Inc. (APTO) Company Bio


Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. The company was founded in 1986 and is based in Mississauga, Canada.


APTO Latest News Stream


Event/TimeNews Detail
Loading, please wait...

APTO Latest Social Stream


Loading social stream, please wait...

View Full APTO Social Stream

Latest APTO News From Around the Web

Below are the latest news stories about Aptose Biosciences Inc that investors may wish to consider to help them evaluate APTO as an investment opportunity.

Aptose to launch early-stage CG-806 study in acute myeloid leukemia

Aptose Biosciences (APTO) is up 7% premarket in reaction to its announcement that the FDA has signed off on its IND application to initiate a Phase 1a/b clinical study of CG-806, an oral FLT3/BTK inhibitor, in patients with acute myeloid leukemia ((AML)). The company intends to initiate the study in H2 in...

Seeking Alpha | June 29, 2020

Aptose Announces FDA Allowance of IND for Phase 1a/b Study of CG-806 in Acute Myeloid Leukemia

Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the U.S. Food and Drug Administration (FDA) completed its review of the company’s Investigational New Drug (IND) application and has granted IND allowance for the initiation of a Phase 1a/b clinical study of CG-806, the company’s highly potent, oral FLT3/BTK inhibitor, in patients with acute myeloid leukemia (AML). CG-806 is currently in a Phase 1 dose escalation study in patients with B-cell malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphomas (NHL), who have failed or are intolerant to current therapies.

Yahoo | June 29, 2020

Is Aptose Biosciences Inc (APTO) A Good Stock To Buy?

In this article you are going to find out whether hedge funds think Aptose Biosciences Inc (NASDAQ:APTO) is a good investment right now. We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks […]

Yahoo | June 28, 2020

3 “Perfect 10” Stocks Under $10 With Big Upside Potential

Bull or bear market, no investment is a sure thing. Especially in the current financial environment, which remains riddled with uncertainty, finding compelling plays can be challenging for even the most seasoned market watchers. COVID-19 and the lockdowns it triggered have changed the rules of the game, so traditional investing strategies may not be as reliable as they once were. This is where a more comprehensive stock analysis can come in handy.TipRanks has a tool that does just that. Building on eight key factors like analyst ratings, hedge fund and insider activity as well as fundamentals and technicals, the Smart Score collates all of this data and assigns each stock a score ranging from 1 to 10, that indicates where a particular name might be headed.Using TipRanks’ database, we fo...

Yahoo | June 23, 2020

Aptose's CG-806 shows encouraging effect in blood cancer

New clinical data on Aptose Biosciences' (APTO) CG-806, an oral, FLT3/BTK cluster selective kinase inhibitor, was presented at the 25th Congress of the European Hematology Association. Early clinical findings from a Phase 1 a/b dose escalation trial to evaluate the safety and tolerability of CG-806 in patients with relapsed or...

Seeking Alpha | June 12, 2020

Read More 'APTO' Stories Here

APTO Price Returns

1-mo -8.06%
3-mo 7.26%
6-mo 19.93%
1-year 115.95%
3-year 388.72%
5-year 34.85%
YTD 14.64%
2019 196.86%
2018 -14.73%
2017 61.15%
2016 -45.06%
2015 -57.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.902 seconds.